- TLDR Biotech
- Archive
- Page 3
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | October 14 - 15, 2024
Amgen & J&J separately post positive myasthenia gravis data, MeiraGTx's positive Ph1/2 data for promising Parkinson’s gene therapy, Tolerance Bio launches with $17.2M, J&J posts a great Q3, Forbion raises over $2.2B, Pfizer & TRIANA Biomedicines sign molecular glue degrader drug discovery partnership, GSK sues Moderna over alleged mRNA vaccine tech infringement, Notable Labs files for bankruptcy
Biotech & Pharma Updates | October 13 - 14, 2024
Novartis, Daiichi Sankyo land another Enhertu approval in China, Catalent sells New Jersey site to Ardena, GSK notches win in pair of chronic nasal conditions Ph3 trials, Eli Lilly to invest £279M into UK public-private partnership, Lundbeck buys Longboard Pharmaceuticals, Novartis ditches LTP001 in idiopathic pulmonary fibrosis after Ph2 miss, Evonik and SalioGen layoffs, Molecular Templates liquidation
Biotech & Pharma Updates | October 10 - 13, 2024
Pfizer caps off rough week with hemophilia approval, Sanofi finds willing suitor for consumer health division, Teva settles kickbacks accusations for $450M, Eli Lilly spends $200M on Suzhou site expansion, Pharma ads are maybe helpful, FDA grants temporary compounding clearance for Mounjaro & Zepbound API, Turnstone drops 60% of their staff, Gilead MASHes eject button in Yuhan liver disease collab, FDA officially declares IV solution shortage
Biotech & Pharma Updates | October 9 - 10, 2024
Roche’s Itovebi nabs breast cancer approval from FDA, Pfizer’s small molecule prostrate cancer combo posts positive Ph3 data, Novartis antirust investigation by Swiss authorities dropped, Cytovale’s $100M Series D for rapid sepsis risk testing, Nona Biosciences & OverT Bio collab on cell therapies for solid tumors, Gritstone bio declares bankruptcy, CDMOs hearing client concerns over China raw material origins, bluebird bio’s Skysona causes blood cancer in 7 pediatric patients
Biotech & Pharma Updates | October 6 - 9, 2024
Astellas goes deeper into gene therapy with AviadoBio deal, Intellia begins Ph3 CRISPR trial for angioedema, Scholar Rock surprise Ph3 win in SMA, duo of RNA biotechs launch with $100M+ in funding each (Judo Bio, City Therapeutics), Basecamp research nabs $60M raise, trio of biotech IPOs (CAMP4 Therapeutics, Upstream Bio, CeriBell), Orchard Therapeutics teams up with Er-Kim to broaden Libmeldy access, Sage’s Alzheimer’s hopes dashed in Ph2, Pfizer shutters last trial from ReViral acquisition, compounding pharmacies sue FDA over ending Mounjaro & Zepbound shortage designations
Biotech & Pharma Updates | October 3 - 6, 2024
Sanofi makes $875M sale of rare disease asset to Recordati, Editas diverts Cas9 licensing fees to DRI Healthcare for $57M upfront, Ultragenyx ups dosage as Wilson disease gene therapy shows promise, Alnylam drops COVID-19 delivery tech lawsuit against Moderna, BeiGene launches Tevimbra with a 10% discount compared to Merck & Co.’s Keytruda, Texas sues big pharmas and PBMs over insulin price “conspiracy”, J&J continues infectious disease retreat with Dengue fever program cut, EMA investigates connection between hair loss, enlarged prostrate meds & “suicidal ideation” risks
Biotech & Pharma Updates | October 2 - 3, 2024
Wuxi Biologics & WuXi AppTec consider selling some non-China asset, BMS’ Opdivo nabs expanded label, Grifols subsidiary nabs up to $135.2M BARDA biothreat contract, Kurma Partners closes new $155M biotech fund, Legend Biotech unveils plans for new cell therapy R&D Facility, Caliway Biopharmaceuticals rakes in $206M in Taiwan IPO, Flagship signs extensive collaboration with Singapore’s A*STAR, Eli Lilly’s Zepbound & Mounjaro no longer facing US shortages, no reopen date yet for Baxter facility hit by hurricane Helene
Biotech & Pharma Updates | October 1 - 2, 2024
J&J, Eli Lilly both earmark billions for new manufacturing sites, J&J shoots ahead of Pfizer, Astellas’ Xtandi in prostrate cancer head-to-head, Frazier Life Sciences $630M biotech fund, Triveni Bio’s $115M Series B, Lundbeck and Charles River Laboratories AI partnership, Gilead increases HIV antiretroviral access to low- and middle-income countries, AbbVie and AstraZeneca take a big Louisiana L in 340B legal kerfuffle, Verrica Pharmaceuticals plans sales and support staff reduction, AI arms race may increase divide between big pharma and upstart biotechs
Biotech & Pharma Updates | September 30 - October 1, 2024
Kailera launches with $400M and big obesity dreams, Biohaven’s $250M public offering, SK pharmteco drops $260M for new manufacturing site, Zephyrm Bioscience files for Hong Kong stock exchange IPO, BioMarin signs RNA R&D deal with CAMP4, FDA and FTC both urged by US senators to do more (in different ways), J&J, Bayer, Pfizer all post new layoffs (totally 500 jobs), Gritstone bio considers the dreaded “strategic alternatives” as cash pile dwindles, Amgen casually forgets to mention $10.7B in back taxes to investors; class-action suit ensues
Biotech & Pharma Updates | September 29 - 30, 2024
Roche pays $850M upfront for Regor Pharma’s breast cancer assets, Eli Lilly’s thyroid cancer med lands full FDA approval, J&J scores two Ph3 wins in multiple myeloma, DCVC Bio closes oversubscribed $400M fund, BMS & Celgene shareholder suit dismissed by NY federal judge, Prime slashes pipeline and signs up to $3.5B drug development pact with BMS, J&J pauses 340B rebate program roll-out after increased HRSA pressure, Ensoma closes Copenhagen site, Otsuka and Moderna both commit serious marketing faux pas according to UK’s pharma marketing watchdog
Biotech & Pharma Updates | September 26 - 29, 2024
Regeneron, Sanofi’s Dupixent gets FDA ok for label expansion, Bavarian Nordic lands another mpox vaccine contract, BlueRock, Bayer showcase 24 month safety data for Parkinson’s disease cell therapy, Cassava’s $40M SEC settlement, Travere halts Ph3 due to drug substance issue, J&J gets final warning letter from HRSA to halt 340B rebate program
Biotech & Pharma Updates | September 25 - 26, 2024
BMS’s historic schizophrenia FDA approval, ARCH Venture Partners $3B 13th fund, Genentech touts positive Ph3 Gazyva lupus data, CSL Seqirus nabs another BARDA bird flu contract, Mirai Bio launches as Flagship’s newest endeavour, Novo Nordisk & Evotec partner to develop off-the-shelf stem-cell derived cell therapies, Inventiva’s coffers are weeks from running dry, Biogen and Sage discontinue essential tremor partnership, FDA adcomm advises narrower PD-1 inhibitor approvals, top NIH neuroscientist conducted alleged widespread Parkinson’s & Alzheimer's research misconduct